APA (7th ed.) Citation

E, K., SC, L., YS, Y., YH, W., & CN, H. (2025). Comparative cardiovascular risks of canagliflozin and selective SGLT2 inhibitors in type 2 diabetes. Frontiers in pharmacology, 16, 1686851. https://doi.org/10.3389/fphar.2025.1686851

Chicago Style (17th ed.) Citation

E, Kornelius, Lo SC, Yang YS, Wang YH, and Huang CN. "Comparative Cardiovascular Risks of Canagliflozin and Selective SGLT2 Inhibitors in Type 2 Diabetes." Frontiers in Pharmacology 16 (2025): 1686851. https://doi.org/10.3389/fphar.2025.1686851.

MLA (9th ed.) Citation

E, Kornelius, et al. "Comparative Cardiovascular Risks of Canagliflozin and Selective SGLT2 Inhibitors in Type 2 Diabetes." Frontiers in Pharmacology, vol. 16, 2025, p. 1686851, https://doi.org/10.3389/fphar.2025.1686851.